How does ibogaine reduce opioid withdrawal?

The leading hypothesis is that ibogaine dampens glutamate overactivity through NMDA antagonism, modulates opioid stress and reward signaling, and changes monoamine tone while noribogaine extends anti-craving effects. Observational reports describe 70–80% withdrawal reduction within hours, but randomized placebo-controlled data are still pending.

Is ibogaine a classic psychedelic?

No. It can produce a long visionary state, but pharmacologically it is broader than classical 5-HT2A psychedelics such as psilocybin or LSD. Its proposed addiction effects involve NMDA, kappa-opioid, sigma-1, serotonin, dopamine, and transporter systems.

How long does ibogaine last?

The acute ibogaine experience commonly lasts 24–36 hours. Noribogaine, its active metabolite, can persist for days and may help explain the sustained anti-craving and mood effects reported after the acute phase.

What is noribogaine and why does it matter?

Noribogaine is ibogaine’s main active metabolite. It acts partly as a serotonin reuptake inhibitor and kappa-opioid modulator, extending pharmacologic effects after the initial ibogaine session. In 2026, noribogaine HCl entered FDA-cleared Phase 1 study for alcohol use disorder.

Does ibogaine cure addiction?

No responsible source should call it a cure. Ibogaine may interrupt withdrawal and drug-seeking circuits, but durability depends on medical selection, integration therapy, continuing addiction care, psychiatric support, and environment.

What are the biggest ibogaine safety risks?

The major acute concern is cardiac risk, especially QTc prolongation through hERG-channel effects, medication interactions, electrolyte abnormalities, and pre-existing heart disease. Clinical screening and continuous monitoring are essential.

Is ibogaine legal in the United States in 2026?

Ibogaine itself remains Schedule I federally. However, state-funded research programs in Texas and Arizona and FDA-cleared noribogaine research have expanded regulated pathways for study. Access outside trials remains legally constrained.

Can ibogaine help PTSD or TBI?

Early human and translational data are promising but not definitive. A 2024 Stanford Nature Medicine study in 30 veterans reported large reductions in PTSD, depression, and cognitive impairment after ibogaine treatment; controlled trials are needed.

Who should not use ibogaine?

People with long-QT risk, significant cardiac disease, uncontrolled psychosis or mania risk, pregnancy, severe hepatic instability, dangerous medication interactions, or lack of clinical monitoring should not pursue ibogaine outside regulated medical research.

Contact | Iboganism

Contact

Iboganism welcomes corrections, questions, and feedback about our coverage and resources. We maintain a cautious, evidence-first editorial approach and value clear, verifiable input from readers researching ibogaine.

If you are seeking to contact the project for corrections or editorial inquiries, please check the About page for the site's published channels and editorial approach. For operational details about treatment programs, consult clinics and regulatory sources.

Iboganism — independent information

How to reach Iboganism

At present, Iboganism does not publish a direct email or phone number on this page. The site can be reached through its published channels; please check back for contact details if you need to submit corrections or source material.

For information about our editorial approach and the standards that guide corrections, see our detailed editorial statement on the About page, which explains sourcing, evidence thresholds, and disclosure practices.

A short invitation

We welcome factual corrections, citation suggestions, and feedback that helps maintain accuracy for people researching ibogaine. If you represent an institution with verifiable documents to share, note that we prefer primary-source citations and official reports.

Editorial note

Iboganism is an independent information resource. It is not a clinic, medical provider, or licensed treatment center, and its content is not medical or legal advice.

Contact

How to reach Iboganism

A short invitation

Editorial note

Related reading (site)